Uncategorized
FDA approves ReNeuron’s cryopreserved formulation of retinal stem cell therapy candidate
The FDA has approved the cryopreserved formulation of ReNeuron Group’s human retinal progenitor cell therapeutic candidate, according to a company press release. Patients with retinitis pigmentosa are now being treated with the formulation in a phase 1/2 clinical trial. The formulation allows cells to be frozen for shipping and storage and thawed for clinical use, increasing shelf life and lowering cost, the release said.